Results 131 to 140 of about 1,193 (178)

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial

BJU International, Volume 135, Issue 4, Page 638-647, April 2025.
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui, Marlene Elmelund, Niels Klarskov   +2 more
wiley   +1 more source

New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology? [PDF]

Pharmaceuticals (Basel)
Bozzatello P, Novelli R, Schisano R, Brasso C, Rocca P, Bellino S.   +5 more
europepmc   +1 more source

Latent Profile Analysis of Challenging Behaviour in Individuals With Intellectual Disabilities: Examining Associated Factors and Life Satisfaction

British Journal of Learning Disabilities, EarlyView.
ABSTRACT Background Challenging behaviours (CBs) are known to adversely affect life satisfaction among individuals with intellectual disabilities. Little is known about the impact of different profiles of CBs amongst individuals with intellectual disabilities in South Korea.
Yesang Cho
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment? [PDF]

Biomedicines
Chrysavgis L, Mourelatou NG, Cholongitas E.   +2 more
europepmc   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Anticonvulsant Potential of the Essential Oil of <i>Croton Heliotropiifolius</i> Kunth: In Vivo and In Silico Approach. [PDF]

ACS Omega
da Cunha MES, Soares AL, Lima EMS, Filho FAS, Ramos RM, Marques RB, de Andrade FDCP, Mendes AN, Martins EPS.   +8 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Profiles of polysubstance use among people reporting past 12-month sleep-motivated nonmedical use of prescription tranquilizers/sedatives. [PDF]

Am J Addict
Falise AM, Prasanna Surendran P, Hoeflich CC, Striley CW, LaMontagne L, Lopez-Quintero C.   +5 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source